WO2009028411A1 - 腫瘍細胞による免疫抑制の解除剤とそれを用いた抗腫瘍剤 - Google Patents
腫瘍細胞による免疫抑制の解除剤とそれを用いた抗腫瘍剤 Download PDFInfo
- Publication number
- WO2009028411A1 WO2009028411A1 PCT/JP2008/064987 JP2008064987W WO2009028411A1 WO 2009028411 A1 WO2009028411 A1 WO 2009028411A1 JP 2008064987 W JP2008064987 W JP 2008064987W WO 2009028411 A1 WO2009028411 A1 WO 2009028411A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- agent
- cell
- immunosuppression
- gene expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/148—Transforming growth factor alpha [TGF-a]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1157—Monocytes, macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/674,881 US20100291677A1 (en) | 2007-08-24 | 2008-08-22 | Reducer of immunosuppression by tumor cell and antitumor agent using the same |
CN200880110043A CN101808664A (zh) | 2007-08-24 | 2008-08-22 | 肿瘤细胞所导致的免疫抑制的解除剂及使用该解除剂的抗肿瘤剂 |
JP2009530080A JP5641599B2 (ja) | 2007-08-24 | 2008-08-22 | 腫瘍細胞による免疫抑制の解除剤とそれを用いた抗腫瘍剤 |
EP08792646.5A EP2193805A4 (en) | 2007-08-24 | 2008-08-22 | IMMUNOSUPPRESSION WEANING AGENT COMPRISING A TUMOR CELL AND ANTI-TUMOR AGENT USING THE SAME |
US13/627,655 US9169324B2 (en) | 2007-08-24 | 2012-09-26 | Reducer of immunosuppression by tumor cell and antitumor agent using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007218977 | 2007-08-24 | ||
JP2007-218977 | 2007-08-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/674,881 A-371-Of-International US20100291677A1 (en) | 2007-08-24 | 2008-08-22 | Reducer of immunosuppression by tumor cell and antitumor agent using the same |
US13/627,655 Continuation US9169324B2 (en) | 2007-08-24 | 2012-09-26 | Reducer of immunosuppression by tumor cell and antitumor agent using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009028411A1 true WO2009028411A1 (ja) | 2009-03-05 |
Family
ID=40387133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/064987 WO2009028411A1 (ja) | 2007-08-24 | 2008-08-22 | 腫瘍細胞による免疫抑制の解除剤とそれを用いた抗腫瘍剤 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20100291677A1 (ja) |
EP (2) | EP2193805A4 (ja) |
JP (1) | JP5641599B2 (ja) |
CN (2) | CN103223165B (ja) |
WO (1) | WO2009028411A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011122611A1 (ja) * | 2010-03-30 | 2011-10-06 | 学校法人慶應義塾 | がんワクチン |
WO2016133059A1 (ja) * | 2015-02-16 | 2016-08-25 | 株式会社ファーマフーズ | Fstl1を利用した抗がん剤・転移抑制剤およびその併用剤 |
JP2016529892A (ja) * | 2013-08-01 | 2016-09-29 | ユニベルシテ カソリク デ ロウバイン | 抗garpタンパク質及びその使用 |
JP2017079741A (ja) * | 2016-11-15 | 2017-05-18 | 国立大学法人三重大学 | 線維症予防又は治療剤 |
WO2018025869A1 (ja) * | 2016-08-01 | 2018-02-08 | 株式会社ファーマフーズ | がん患者におけるfstl1阻害剤による治療効果を予測するためのバイオマーカー |
WO2018186032A1 (ja) * | 2017-04-05 | 2018-10-11 | 国立大学法人千葉大学 | Swi/snf複合体の機能阻害剤 |
JP2019112363A (ja) * | 2017-12-25 | 2019-07-11 | 小林製薬株式会社 | 制御性t細胞分化抑制剤、及び免疫調節用組成物 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2981822T (pt) | 2013-05-06 | 2020-12-07 | Scholar Rock Inc | Composições e métodos para modulação do fator de crescimento |
WO2015171691A2 (en) * | 2014-05-06 | 2015-11-12 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
JP2020518569A (ja) * | 2017-04-28 | 2020-06-25 | リサーチ アンド ビジネス ファウンデーション ソンギュンクァン ユニバーシティ | Foxp3を発現する樹状細胞の癌の診断または治療のための用途 |
CN116870167A (zh) * | 2023-08-24 | 2023-10-13 | 四川大学 | 一种用于治疗实体肿瘤的联合用药物和药物组合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005062972A2 (en) * | 2003-12-23 | 2005-07-14 | Tanox, Inc. | Treatment of cancer with novel anti-il 13 monoclonal antibodies |
JP2005526842A (ja) * | 2002-03-22 | 2005-09-08 | ザ ペン ステート リサーチ ファウンデーション | 癌免疫療法 |
JP2005536534A (ja) * | 2002-08-19 | 2005-12-02 | アブジェニックス・インコーポレーテッド | 単球走化性タンパク質−1(mcp−1)に対する抗体、およびその使用 |
JP2006206538A (ja) * | 2005-01-31 | 2006-08-10 | Institute Of Physical & Chemical Research | 抗原提示細胞の機能制御剤 |
WO2006109301A2 (en) * | 2005-04-15 | 2006-10-19 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating mcp-1/ccr2 associated diseases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0478101B1 (en) * | 1990-09-24 | 2001-08-29 | W.R. Grace & Co.-Conn. | Therapeutic use of peptides having thrombospondin-like activity |
WO2004087758A2 (en) * | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
-
2008
- 2008-08-22 WO PCT/JP2008/064987 patent/WO2009028411A1/ja active Application Filing
- 2008-08-22 EP EP08792646.5A patent/EP2193805A4/en not_active Ceased
- 2008-08-22 EP EP16201981.4A patent/EP3178496A1/en not_active Withdrawn
- 2008-08-22 US US12/674,881 patent/US20100291677A1/en not_active Abandoned
- 2008-08-22 CN CN201210408856.3A patent/CN103223165B/zh not_active Expired - Fee Related
- 2008-08-22 JP JP2009530080A patent/JP5641599B2/ja not_active Expired - Fee Related
- 2008-08-22 CN CN200880110043A patent/CN101808664A/zh active Pending
-
2012
- 2012-09-26 US US13/627,655 patent/US9169324B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005526842A (ja) * | 2002-03-22 | 2005-09-08 | ザ ペン ステート リサーチ ファウンデーション | 癌免疫療法 |
JP2005536534A (ja) * | 2002-08-19 | 2005-12-02 | アブジェニックス・インコーポレーテッド | 単球走化性タンパク質−1(mcp−1)に対する抗体、およびその使用 |
WO2005062972A2 (en) * | 2003-12-23 | 2005-07-14 | Tanox, Inc. | Treatment of cancer with novel anti-il 13 monoclonal antibodies |
JP2006206538A (ja) * | 2005-01-31 | 2006-08-10 | Institute Of Physical & Chemical Research | 抗原提示細胞の機能制御剤 |
WO2006109301A2 (en) * | 2005-04-15 | 2006-10-19 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating mcp-1/ccr2 associated diseases |
Non-Patent Citations (35)
Title |
---|
"Current Protocols in Molecular Biology", JOHN WILEY & SONS LTD. |
"Molecular cloning, a laboratory manual", 2001, COLD SPRING HARBOR PRESS |
ANDALOUSSI; LESNIAK, NEURO-ONCOLOGY, vol. 8, 2006, pages 234 - 243 |
ATABANI ET AL., EUR. J. IMMUNOL., vol. 35, 2005, pages 2157 - 2162 |
ATSUSHI MIYOSHI ET AL.: "Tensha Inshi Snail, SIP1 wa Kangan Saibo no E-cadherin Idenshi Hatsugen o Yokusei suru to Tomoni Shinjunno o Koshin Saseru", JOURNAL OF JAPAN SURGICAL SOCIETY, vol. 104, 30 April 2003 (2003-04-30) * |
BISIKIRSKA ET AL., J. CLIN. INVEST., vol. 115, 2005, pages 2904 - 2913 |
CASTLE V. ET AL.: "Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 87, no. 6, 1991, pages 1883 - 1888, XP008132040 * |
DEPAOLO R.W. ET AL.: "CC chemokine ligand 2 and its receptor regulate mucosal production of IL -12 and TGF-beta in high dose oral tolerance", THE JOURNAL OF IMMUNOLOGY, vol. 171, no. 7, 2003, pages 3560 - 3567, XP008132036 * |
FICHTNER-FEIGL S. ET AL.: "IL -13 signaling through the IL -13alpha2 receptor is involved in induction of TGF-betal production and fibrosis", NATURE MEDICINE, vol. 12, no. 1, January 2006 (2006-01-01), pages 99 - 106, XP008132037 * |
FONTENOT ET AL., IMMUNITY, vol. 22, 2005, pages 329 - 341 |
FONTENOT ET AL., NAT. IMMUNOL., vol. 4, 2003, pages 330 - 336 |
HICKY ET AL., SEMIN. IMMUNOL., vol. 11, 1998, pages 125 - 137 |
HIROYOSHI NISHIKAWA ET AL.: "Seigyosei T-Saibo ni yoru Men'eki Yokusei to sono Kokufuku -Yuko na Gan Vaccine Ryoho no Kaihatsu ni Mukete", IGAKU NO AYUMI, vol. 221, no. 8, 26 May 2007 (2007-05-26), pages 631 - 636 * |
HORI ET AL., SCIENCE, vol. 299, 2003, pages 1057 - 1061 |
ICHIHARA ET AL., CLIN. CANCER RES., vol. 9, 2003, pages 4404 - 4408 |
JIANG; CHESS, J. CLIN. INVEST., vol. 114, 2004, pages 1198 - 1208 |
JUNKO KAYAO ET AL.: "Hakkekyu Saibo no Shozoki eno Shinjun to sono Saibozo", JOURNAL OF THE JAPANESE SOCIETY OF CLINICAL CYTOLOGY, vol. 44, no. 2, 22 September 2005 (2005-09-22) * |
KAZUHIRO YOKOYAMA ET AL.: "Henpei Johigan no Kodo Shinjunno Kakutoku Katei ni Okeru Snail no Hatsugen to sono Sayo", JOURNAL OF JAPAN SOCIETY FOR ORAL TUMORS, vol. 13, no. 4, 15 December 2001 (2001-12-15), pages 293 - 300 * |
LIYANAGE ET AL., J. IMMUNOL., vol. 169, 2002, pages 2756 - 2761 |
MAMORU IGARASHI ET AL.: "Tensha Inshi SNAIL no Vitamin D Juyotai o Kaishita Hito Daichogan eno Sayo no Kaimei", VITAMINS, vol. 79, no. 12, 25 December 2005 (2005-12-25), pages 595 - 596 * |
MIYARA M. ET AL.: "Natural regulatory T cells: mechanisms of suppression", TRENDS IN MOLECULAR MEDICINE, vol. 13, no. 3, 6 March 2007 (2007-03-06), pages 108 - 116, XP005916667 * |
MIYARA; SAKAGUCHI, TRENDS MOL. MED., vol. 13, 2007, pages 108 - 116 |
NATURE REV CANCER, vol. 7, 2007, pages 415 - 428 |
SAKAGUCHI ET AL., IMMUNOL. REV., vol. 182, 2001, pages 18 - 32 |
SASADA ET AL., CANCER, vol. 98, 2003, pages 1098 - 1099 |
See also references of EP2193805A4 * |
SEO N. ET AL.: "Interleukin-10 expressed at early tumour sites induces subsequent generation of CD 4(+) T-regulatory cells and systemic collapse of antitumour immunity", IMMUNOLOGY, vol. 103, no. 4, 2001, pages 449 - 457, XP008132039 * |
SKAPENKO A. ET AL.: "The IL -4 receptor alpha- chain-binding cytokines, IL -4 and IL -13, induce forkhead box P3-expressing CD 25+ CD 4+ regulatory T cells from CD 25- CD 4+ precursors", JOURNAL OF IMMUNOLOGY, vol. 175, no. 9, 2005, pages 6107 - 6116, XP008132038 * |
TAKASHI MURAKAMI ET AL.: "Seigyosei T-Saibo no Yudo to sono Oyo", TRANSPLANTATION NOW, vol. 20, no. 4, 3 August 2007 (2007-08-03), pages 335 - 340 * |
TURK ET AL., IMMUNOL. REV., vol. 188, 2002, pages 122 - 135 |
WOLF ET AL., CLIN. CANCER RES., vol. 9, 2003, pages 606 - 612 |
WOO ET AL., CANCER RES., vol. 61, 2001, pages 4766 - 4772 |
YANG ET AL., ONCOGENE, vol. 26, 2007, pages 1459 - 1467 |
ZHENG ET AL., J. IMMUNOL., vol. 172, 2004, pages 5213 - 5221 |
ZOSHOKU INSHI: "Cytokine", 1 March 2005, YOGO LIBRARY, pages: 147 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011122611A1 (ja) * | 2010-03-30 | 2011-10-06 | 学校法人慶應義塾 | がんワクチン |
JP2011207832A (ja) * | 2010-03-30 | 2011-10-20 | Keio Gijuku | がんワクチン |
CN103068836A (zh) * | 2010-03-30 | 2013-04-24 | 学校法人庆应义塾 | 癌症疫苗 |
JP7492981B2 (ja) | 2013-08-01 | 2024-05-30 | ユニベルシテ カソリク デ ロウバイン | 抗garpタンパク質及びその使用 |
JP2016529892A (ja) * | 2013-08-01 | 2016-09-29 | ユニベルシテ カソリク デ ロウバイン | 抗garpタンパク質及びその使用 |
JP2022070946A (ja) * | 2013-08-01 | 2022-05-13 | ユニベルシテ カソリク デ ロウバイン | 抗garpタンパク質及びその使用 |
JPWO2016133059A1 (ja) * | 2015-02-16 | 2018-01-18 | 株式会社ファーマフーズ | Fstl1を利用した抗がん剤・転移抑制剤およびその併用剤 |
US10806787B2 (en) | 2015-02-16 | 2020-10-20 | Pharma Foods International Co., Ltd. | Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof |
WO2016133059A1 (ja) * | 2015-02-16 | 2016-08-25 | 株式会社ファーマフーズ | Fstl1を利用した抗がん剤・転移抑制剤およびその併用剤 |
WO2018025869A1 (ja) * | 2016-08-01 | 2018-02-08 | 株式会社ファーマフーズ | がん患者におけるfstl1阻害剤による治療効果を予測するためのバイオマーカー |
JPWO2018025869A1 (ja) * | 2016-08-01 | 2019-07-11 | 株式会社ファーマフーズ | がん患者におけるfstl1阻害剤による治療効果を予測するためのバイオマーカー |
JP7012363B2 (ja) | 2016-08-01 | 2022-01-28 | 株式会社ファーマフーズ | がん患者におけるfstl1阻害剤による治療効果を予測するためのバイオマーカー |
JP2017079741A (ja) * | 2016-11-15 | 2017-05-18 | 国立大学法人三重大学 | 線維症予防又は治療剤 |
WO2018186032A1 (ja) * | 2017-04-05 | 2018-10-11 | 国立大学法人千葉大学 | Swi/snf複合体の機能阻害剤 |
JP2019112363A (ja) * | 2017-12-25 | 2019-07-11 | 小林製薬株式会社 | 制御性t細胞分化抑制剤、及び免疫調節用組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20100291677A1 (en) | 2010-11-18 |
US20130115225A1 (en) | 2013-05-09 |
EP3178496A1 (en) | 2017-06-14 |
US9169324B2 (en) | 2015-10-27 |
CN103223165B (zh) | 2015-02-11 |
CN101808664A (zh) | 2010-08-18 |
CN103223165A (zh) | 2013-07-31 |
JPWO2009028411A1 (ja) | 2010-12-02 |
JP5641599B2 (ja) | 2014-12-17 |
EP2193805A4 (en) | 2013-09-04 |
EP2193805A1 (en) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009028411A1 (ja) | 腫瘍細胞による免疫抑制の解除剤とそれを用いた抗腫瘍剤 | |
AU2018256633A1 (en) | Therapy for enteric infections | |
Knoell et al. | Impact of zinc metabolism on innate immune function in the setting of sepsis | |
JO3449B1 (ar) | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب | |
UA100682C2 (ru) | АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ | |
EP1983048A4 (en) | NEW PROTEIN EXPRESSION SYSTEM | |
TW200806317A (en) | Methods for reducing protein aggregation | |
AU2012283775A8 (en) | Inhibitors of Bruton's tyrosine kinase | |
MX355469B (es) | Complejos de proteinas de citomegalovirus. | |
MY152033A (en) | Anti-siglec-15 antibody | |
WO2010057203A3 (en) | Hdl particles for delivery of nucleic acids | |
WO2012045082A3 (en) | Engineered nucleic acids and methods of use thereof | |
MA34722B1 (fr) | Méthodes et compositions pour l'immunothérapie de maladies neurales | |
EP1783209A4 (en) | SELECTIVE CULTURE METHOD AND SEPARATION METHOD FOR SMALL HEPATOCYTES USING HYALURONIC ACID | |
EP1733039A4 (en) | IMPROVED BACTERIA CELL FOR DIRECT EXPRESSION OF PEPTIDES | |
WO2012010974A8 (en) | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia | |
WO2007030560A3 (en) | Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents | |
IL177244A0 (en) | Astaxanthin, esters thereof and compositions containing them, for regulating gene expression, and their use in the manufacture of medicaments | |
MX2011012048A (es) | Metodos y composiciones para el tratamiento del lupus. | |
WO2008069942A3 (en) | Novel methods of enhancing delivery of a gene therapy vector using steroids | |
GB201013215D0 (en) | Expression of antibody or a fragment thereof in lactobacillus | |
WO2009014404A3 (en) | Multifunctional protein simultaneously delivering antibodies and nanoparticles | |
WO2010100515A3 (en) | Fractions of wheat germ ferment | |
Yu et al. | Increased airway epithelial cell–derived exosomes activate macrophage‐mediated allergic inflammation via CD100 shedding | |
Henke et al. | The fungal lactone oxacyclododecindione is a potential new therapeutic substance in the treatment of lupus-associated kidney disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880110043.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08792646 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009530080 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2008792646 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008792646 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12674881 Country of ref document: US |